1. Home
  2. NTCT vs NUVB Comparison

NTCT vs NUVB Comparison

Compare NTCT & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NetScout Systems Inc.

NTCT

NetScout Systems Inc.

SELL

Current Price

$39.64

Market Cap

2.0B

Sector

Technology

ML Signal

SELL

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$5.52

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTCT
NUVB
Founded
1984
2018
Country
United States
United States
Employees
N/A
307
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.7B
IPO Year
1999
N/A

Fundamental Metrics

Financial Performance
Metric
NTCT
NUVB
Price
$39.64
$5.52
Analyst Decision
Buy
Strong Buy
Analyst Count
2
8
Target Price
$31.00
$11.38
AVG Volume (30 Days)
665.7K
4.3M
Earning Date
05-07-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
125.39
N/A
EPS
1.30
N/A
Revenue
$891,820,000.00
N/A
Revenue This Year
$6.02
$203.82
Revenue Next Year
$2.55
$58.18
P/E Ratio
$30.52
N/A
Revenue Growth
N/A
N/A
52 Week Low
$20.40
$1.87
52 Week High
$43.80
$9.75

Technical Indicators

Market Signals
Indicator
NTCT
NUVB
Relative Strength Index (RSI) 49.00 65.32
Support Level $38.38 $5.22
Resistance Level $40.92 $6.06
Average True Range (ATR) 1.44 0.39
MACD -0.48 0.07
Stochastic Oscillator 20.27 93.28

Price Performance

Historical Comparison
NTCT
NUVB

About NTCT NetScout Systems Inc.

NetScout Systems Inc is a provider of service assurance and cybersecurity solutions to enterprise and government networks. It bases its solutions on proprietary adaptive service intelligence technology, which helps customers monitor and identify performance issues and provides insight into network-based security threats. These solutions also deliver real-time and historical information, which provides insight to restore service and understand the quality of user experience. The company derives revenue from the sale of network management tools and security solutions. Its geographical regions include USA, which derives maximum revenue, Europe, Asia, and Rest of the World.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: